1. Protein Tyrosine Kinase/RTK
  2. c-Fms
  3. GW2580

GW2580 is an orally bioavailable and selective inhibitor of c-Fms kinase which completely inhibits human cFMS kinase in vitro at 0.06 μM. GW2580 acts as a competitive inhibitor of ATP binding to the cFMS kinase and inhibits colony-stimulating-factor-1 signaling.

For research use only. We do not sell to patients.

CAS No. : 870483-87-7

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg In-stock
500 mg In-stock
1 g In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 13 publication(s) in Google Scholar

Other Forms of GW2580:

Top Publications Citing Use of Products

    GW2580 purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2022 May 2;19:474-485.  [Abstract]

    GW2580 (10 μM) exhibited an efficient inhibition of phosphorylation of CSF-1R and phosphorylation of AKT.

    GW2580 purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2022 May 2;19:474-485.  [Abstract]

    Confocal microscope images show mBMSCs morphology on CPC, CPC/hydrogel and CPC/hydrogel/GW2580 (50 mg/kg) scaffolds after 3 days of coculture.

    GW2580 purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2022 May 2;19:474-485.  [Abstract]

    GW2580 (50 mg/kg) loaded scaffolds inhibited tumor growth more efficiently than the untreated and CPC scaffold group by IVIS images.

    GW2580 purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2022 May 2;19:474-485.  [Abstract]

    GW2580 (50 mg/kg)-loaded scaffolds effectively inhibit 4T1 breast tumor growth in a mice model.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    GW2580 is an orally bioavailable and selective inhibitor of c-Fms kinase which completely inhibits human cFMS kinase in vitro at 0.06 μM. GW2580 acts as a competitive inhibitor of ATP binding to the cFMS kinase and inhibits colony-stimulating-factor-1 signaling[1].

    IC50 & Target

    IC50: 60 nM (c-FMS)

    Cellular Effect
    Cell Line Type Value Description References
    A549 IC50
    > 30 μM
    Compound: GW2580
    Growth inhibition of serum-stimulated human A549 cells after 3 days by spectrophotometry
    Growth inhibition of serum-stimulated human A549 cells after 3 days by spectrophotometry
    [PMID: 16249345]
    BT-474 IC50
    21 μM
    Compound: GW2580
    Growth inhibition of serum-stimulated human BT474 cells after 3 days by spectrophotometry
    Growth inhibition of serum-stimulated human BT474 cells after 3 days by spectrophotometry
    [PMID: 16249345]
    HFF IC50
    > 30 μM
    Compound: GW2580
    Growth inhibition of serum-stimulated HFF after 3 days by spectrophotometry
    Growth inhibition of serum-stimulated HFF after 3 days by spectrophotometry
    [PMID: 16249345]
    HN5 IC50
    29 μM
    Compound: GW2580
    Growth inhibition of serum-stimulated human HN5 cells after 3 days by spectrophotometry
    Growth inhibition of serum-stimulated human HN5 cells after 3 days by spectrophotometry
    [PMID: 16249345]
    HUVEC IC50
    12 μM
    Compound: GW2580
    Growth inhibition of VEGF-stimulated HUVEC after 3 days by spectrophotometry
    Growth inhibition of VEGF-stimulated HUVEC after 3 days by spectrophotometry
    [PMID: 16249345]
    HUVEC IC50
    > 10 μM
    Compound: GW2580
    Growth inhibition of bFGF-stimulated HUVEC after 3 days by spectrophotometry
    Growth inhibition of bFGF-stimulated HUVEC after 3 days by spectrophotometry
    [PMID: 16249345]
    MDA-MB-231 IC50
    > 30 μM
    Compound: GW2580
    Growth inhibition of serum-stimulated human MDA231 cells after 3 days by spectrophotometry
    Growth inhibition of serum-stimulated human MDA231 cells after 3 days by spectrophotometry
    [PMID: 16249345]
    Monocyte IC50
    0.47 μM
    Compound: GW2580
    Growth inhibition of CSF-1-stimulated freshly isolated human monocytes after 3 days by spectrophotometry
    Growth inhibition of CSF-1-stimulated freshly isolated human monocytes after 3 days by spectrophotometry
    [PMID: 16249345]
    NCI-N87 IC50
    > 30 μM
    Compound: GW2580
    Growth inhibition of serum-stimulated human NCI-N87 cells after 3 days by spectrophotometry
    Growth inhibition of serum-stimulated human NCI-N87 cells after 3 days by spectrophotometry
    [PMID: 16249345]
    NFS-60 GI50
    94 nM
    Compound: GW-2580
    Growth inhibition of mouse NFS60 cells after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    Growth inhibition of mouse NFS60 cells after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    [PMID: 30522957]
    NFS-60 IC50
    0.33 μM
    Compound: GW2580
    Growth inhibition of CSF1-stimulated mouse M-NFS-60 cells after 3 days by spectrophotometry
    Growth inhibition of CSF1-stimulated mouse M-NFS-60 cells after 3 days by spectrophotometry
    [PMID: 16249345]
    NSO IC50
    13.5 μM
    Compound: GW2580
    Growth inhibition of serum-stimulated mouse NSO cells after 3 days by spectrophotometry
    Growth inhibition of serum-stimulated mouse NSO cells after 3 days by spectrophotometry
    [PMID: 16249345]
    Sf21 IC50
    3 nM
    Compound: GW-2580
    Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP
    Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP
    [PMID: 30522957]
    In Vitro

    GW2580 completely inhibits the growth of CSF-1-dependent mouse myeloid M-NFS-60 cells at 0.7 μM. GW2580 at 0.8-1 μM completely blocks the ability of CSF-1 to induce the growth of mouse M-NFS60 myeloid cells and human monocytes[1].
    GW2580 causes a 30-40% inhibition of PTH-induced calcium release at 0.1-0.3 μM, with higher concentrations of 1, 3, and 10 μM completely inhibiting the PTH response[1].
    GW2580 inhibits CSF1R phosphorylation in RAW264.7 murine macrophages stimulated with 10 ng/mL with IC50 of approximately 10 nM[2].
    GW2580 also inhibits TRKA activity with IC50 of 0.88 μM[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    GW2580 (Oral administration; 20 and 80 mg/kg) produces a dose-related decrease in the number of tumor cells, with the 80 mg/kg dose completely blocking tumor growth[1].
    GW2580 (Oral administration; 20 and 80 mg/kg) has gave maximal plasma concentrations of 1.4 and 5.6 μM, respectively[1].
    GW2580 (50 mg/kg; twice a day from days 0 to 21, 7 to 21, or 14 to 21) inhibits joint connective tissue and bone destruction in a 21-day adjuvant arthritis model[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Female C3H/HEN mice or female CD-1 nude mice weighing 22-26 g[1]
    Dosage: 20 and 80 mg/kg
    Administration: Oral administration
    Result: Produced a dose-related decrease in the number of tumor cells, with the 80 mg/kg dose completely blocking tumor growth.
    Animal Model: Female C3H/HEN mice or female CD-1 nude mice weighing 22-26 g[1]
    Dosage: 20 and 80 mg/kg (Pharmacokinetic Study)
    Administration: Oral administration
    Result: Had gave maximal plasma concentrations of 1.4 and 5.6 μM, respectively.
    Molecular Weight

    366.41

    Formula

    C20H22N4O3

    CAS No.
    Appearance

    Solid

    Color

    White to yellow

    SMILES

    NC1=NC(N)=C(CC2=CC(OC)=C(OCC3=CC=C(OC)C=C3)C=C2)C=N1

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 33.33 mg/mL (90.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Ethanol : < 1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.7292 mL 13.6459 mL 27.2918 mL
    5 mM 0.5458 mL 2.7292 mL 5.4584 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (5.68 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (5.68 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  0.5% CMC-Na/saline water

      Solubility: 5 mg/mL (13.65 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.90%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.7292 mL 13.6459 mL 27.2918 mL 68.2296 mL
    5 mM 0.5458 mL 2.7292 mL 5.4584 mL 13.6459 mL
    10 mM 0.2729 mL 1.3646 mL 2.7292 mL 6.8230 mL
    15 mM 0.1819 mL 0.9097 mL 1.8195 mL 4.5486 mL
    20 mM 0.1365 mL 0.6823 mL 1.3646 mL 3.4115 mL
    25 mM 0.1092 mL 0.5458 mL 1.0917 mL 2.7292 mL
    30 mM 0.0910 mL 0.4549 mL 0.9097 mL 2.2743 mL
    40 mM 0.0682 mL 0.3411 mL 0.6823 mL 1.7057 mL
    50 mM 0.0546 mL 0.2729 mL 0.5458 mL 1.3646 mL
    60 mM 0.0455 mL 0.2274 mL 0.4549 mL 1.1372 mL
    80 mM 0.0341 mL 0.1706 mL 0.3411 mL 0.8529 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    GW2580
    Cat. No.:
    HY-10917
    Quantity:
    MCE Japan Authorized Agent: